About natalizumab
Monoclonal antibody; integrin antagonist
Used for
- Relapsing forms of multiple sclerosis in adults
- Moderate-to-severe Crohn’s disease after inadequate response to other treatments
Usual adult dose
Multiple sclerosis: 300 mg intravenously every 4 weeks. Crohn’s disease: 300 mg intravenously every 4 weeks.
Common side effects
- Headache
- Fatigue
- Joint pain
- Infusion reactions
Important warnings
- Can cause rare, potentially fatal progressive multifocal leukoencephalopathy (PML).
- Risk of PML increases with JC virus antibodies, longer treatment, or prior immunosuppressant use.
- Serious infections and liver injury can occur.
- Treatment is restricted through a safety monitoring program in many countries.
Pregnancy
May cause fetal harm; pregnancy data are limited. Use requires careful consideration of benefits and risks.
Breastfeeding
Natalizumab may enter breast milk; effects on infants are uncertain.
Interactions
- Other immunosuppressants or immunomodulators may increase infection risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.